Tags

Type your tag names separated by a space and hit enter

Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
Diagn Microbiol Infect Dis. 2002 Aug; 43(4):303-9.DM

Abstract

The antimicrobial activity of garenoxacin, a des-(6)F quinolone (formally BMS284756 and T-3811), was evaluated against 2,537 skin and soft tissue infection (SSTI) isolates from the SENTRY Antimicrobial Surveillance Program. Strains isolated in 2000 from Europe, North and Latin America were tested at a central laboratory using reference broth microdilution methods. The rank order of the seven most frequent SSTI pathogens was: Staphylococcus aureus (39.9%), Pseudomonas aeruginosa (12.1%), Escherichia coli (9.7%), Enterococcus spp. (7.7%), Klebsiella spp. (5.8%), Enterobacter spp. (5.6%) and coagulase-negative staphylococci (CoNS; 4.2%). Garenoxacin exhibited a four-fold greater activity (MIC(90), 0.06 microg/ml) compared to levofloxacin (MIC(90), 0.25 microg/ml) against oxacillin-susceptible S. aureus; and oxacillin-resistant staphylococci were more susceptible to garenoxacin (>/=90.5%) at </=4 microg/ml than ciprofloxacin or levofloxacin. Enterococcus spp. were more susceptible to garenoxacin and gatifloxacin (MIC(50), 0.5 microg/ml) than ciprofloxacin or levofloxacin (MIC(50), 2 microg/ml). All tested quinolones inhibited 64.7 to 69.7% of P. aeruginosa isolates, and the rank order of potency slightly favored ciprofloxacin (MIC(50), </=0.25 microg/ml). Similar susceptibility rates for the four quinolones were observed against E. coli (85.8-87.0%), Enterobacter spp. (90.8-94.3%) and Klebsiella spp. (89.8-95.2%) with the greatest levels of resistance recorded in Latin America for E. coli and Enterobacter spp. The occurrence of extended spectrum beta-lactamase-producing isolates (predominantly K. pneumoniae) was documented in all three monitored regions (Latin America > Europe > North America). Continued development of garenoxacin as a treatment of pathogens that commonly cause SSTIs appears to be warranted.

Authors+Show Affiliations

The JONES Group/JMI Laboratories, North Liberty, Iowa, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12151191

Citation

Kirby, Jeffrey T., et al. "Geographic Variations in Garenoxacin (BMS284756) Activity Tested Against Pathogens Associated With Skin and Soft Tissue Infections: Report From the SENTRY Antimicrobial Surveillance Program (2000)." Diagnostic Microbiology and Infectious Disease, vol. 43, no. 4, 2002, pp. 303-9.
Kirby JT, Mutnick AH, Jones RN, et al. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis. 2002;43(4):303-9.
Kirby, J. T., Mutnick, A. H., Jones, R. N., Biedenbach, D. J., & Pfaller, M. A. (2002). Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagnostic Microbiology and Infectious Disease, 43(4), 303-9.
Kirby JT, et al. Geographic Variations in Garenoxacin (BMS284756) Activity Tested Against Pathogens Associated With Skin and Soft Tissue Infections: Report From the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis. 2002;43(4):303-9. PubMed PMID: 12151191.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). AU - Kirby,Jeffrey T, AU - Mutnick,Alan H, AU - Jones,Ronald N, AU - Biedenbach,Douglas J, AU - Pfaller,Michael A, PY - 2002/8/2/pubmed PY - 2002/9/20/medline PY - 2002/8/2/entrez SP - 303 EP - 9 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 43 IS - 4 N2 - The antimicrobial activity of garenoxacin, a des-(6)F quinolone (formally BMS284756 and T-3811), was evaluated against 2,537 skin and soft tissue infection (SSTI) isolates from the SENTRY Antimicrobial Surveillance Program. Strains isolated in 2000 from Europe, North and Latin America were tested at a central laboratory using reference broth microdilution methods. The rank order of the seven most frequent SSTI pathogens was: Staphylococcus aureus (39.9%), Pseudomonas aeruginosa (12.1%), Escherichia coli (9.7%), Enterococcus spp. (7.7%), Klebsiella spp. (5.8%), Enterobacter spp. (5.6%) and coagulase-negative staphylococci (CoNS; 4.2%). Garenoxacin exhibited a four-fold greater activity (MIC(90), 0.06 microg/ml) compared to levofloxacin (MIC(90), 0.25 microg/ml) against oxacillin-susceptible S. aureus; and oxacillin-resistant staphylococci were more susceptible to garenoxacin (>/=90.5%) at </=4 microg/ml than ciprofloxacin or levofloxacin. Enterococcus spp. were more susceptible to garenoxacin and gatifloxacin (MIC(50), 0.5 microg/ml) than ciprofloxacin or levofloxacin (MIC(50), 2 microg/ml). All tested quinolones inhibited 64.7 to 69.7% of P. aeruginosa isolates, and the rank order of potency slightly favored ciprofloxacin (MIC(50), </=0.25 microg/ml). Similar susceptibility rates for the four quinolones were observed against E. coli (85.8-87.0%), Enterobacter spp. (90.8-94.3%) and Klebsiella spp. (89.8-95.2%) with the greatest levels of resistance recorded in Latin America for E. coli and Enterobacter spp. The occurrence of extended spectrum beta-lactamase-producing isolates (predominantly K. pneumoniae) was documented in all three monitored regions (Latin America > Europe > North America). Continued development of garenoxacin as a treatment of pathogens that commonly cause SSTIs appears to be warranted. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/12151191/Geographic_variations_in_garenoxacin__BMS284756__activity_tested_against_pathogens_associated_with_skin_and_soft_tissue_infections:_report_from_the_SENTRY_Antimicrobial_Surveillance_Program__2000__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732889302004157 DB - PRIME DP - Unbound Medicine ER -